While new ADCs targeting HER2 (such as T-Dxd) have offered hope in preclinical settings, their effectiveness in patients with H2L carcinomas varies and establishing reliable predictive biomarkers is urgently needed. The gene discussed is ERBB2; the disease is carcinoma.